327 related articles for article (PubMed ID: 33923400)
1. The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications.
Li Santi A; Napolitano F; Montuori N; Ragno P
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923400
[TBL] [Abstract][Full Text] [Related]
2. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.
Lund IK; Illemann M; Thurison T; Christensen IJ; Høyer-Hansen G
Curr Drug Targets; 2011 Nov; 12(12):1744-60. PubMed ID: 21707477
[TBL] [Abstract][Full Text] [Related]
3. Biotin-Chasing Assay to Evaluate uPAR Stability and Cleavage on the Surface of Cells.
Leksa V; Schiller HB; Stockinger H
Methods Mol Biol; 2018; 1731():39-47. PubMed ID: 29318541
[TBL] [Abstract][Full Text] [Related]
4. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Pavón MA; Arroyo-Solera I; Céspedes MV; Casanova I; León X; Mangues R
Oncotarget; 2016 Aug; 7(35):57351-57366. PubMed ID: 27385000
[TBL] [Abstract][Full Text] [Related]
5. Urokinase Type Plasminogen Activator and the Molecular Mechanisms of its Regulation in Cancer.
Santibanez JF
Protein Pept Lett; 2017; 24(10):936-946. PubMed ID: 28820062
[TBL] [Abstract][Full Text] [Related]
6. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer.
Mazar AP
Anticancer Drugs; 2001 Jun; 12(5):387-400. PubMed ID: 11395568
[TBL] [Abstract][Full Text] [Related]
7. Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator.
Kindzelskii AL; Amhad I; Keller D; Zhou MJ; Haugland RP; Garni-Wagner BA; Gyetko MR; Todd RF; Petty HR
Histochem Cell Biol; 2004 Apr; 121(4):299-310. PubMed ID: 15042374
[TBL] [Abstract][Full Text] [Related]
8. Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy.
Li D; Liu S; Shan H; Conti P; Li Z
Theranostics; 2013; 3(7):507-15. PubMed ID: 23843898
[TBL] [Abstract][Full Text] [Related]
9. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling.
Blasi F; Sidenius N
FEBS Lett; 2010 May; 584(9):1923-30. PubMed ID: 20036661
[TBL] [Abstract][Full Text] [Related]
10. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
11. Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
Saldanha RG; Xu N; Molloy MP; Veal DA; Baker MS
J Proteome Res; 2008 Nov; 7(11):4792-806. PubMed ID: 18808175
[TBL] [Abstract][Full Text] [Related]
12. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.
Sidenius N; Blasi F
Cancer Metastasis Rev; 2003; 22(2-3):205-22. PubMed ID: 12784997
[TBL] [Abstract][Full Text] [Related]
13. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
[TBL] [Abstract][Full Text] [Related]
14. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract][Full Text] [Related]
15. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
Nagase K; Kobayashi H; Yoshikawa E; Kurita N
J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
[TBL] [Abstract][Full Text] [Related]
16. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling.
Carriero MV; Stoppelli MP
Curr Pharm Des; 2011; 17(19):1944-61. PubMed ID: 21711235
[TBL] [Abstract][Full Text] [Related]
17. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
Mauro CD; Pesapane A; Formisano L; Rosa R; D'Amato V; Ciciola P; Servetto A; Marciano R; Orsini RC; Monteleone F; Zambrano N; Fontanini G; Servadio A; Pignataro G; Grumetto L; Lavecchia A; Bruzzese D; Iaccarino A; Troncone G; Veneziani BM; Montuori N; Placido S; Bianco R
Sci Rep; 2017 Aug; 7(1):9388. PubMed ID: 28839232
[TBL] [Abstract][Full Text] [Related]
19. The effects of amino-acid mutations on specific interactions between urokinase-type plasminogen activator and its receptor: Ab initio molecular orbital calculations.
Tsuji S; Kasumi T; Nagase K; Yoshikawa E; Kobayashi H; Kurita N
J Mol Graph Model; 2011 Aug; 29(8):975-84. PubMed ID: 21605990
[TBL] [Abstract][Full Text] [Related]
20. Expression and localization of urokinase-type plasminogen activator receptor in bovine cumulus-oocyte complexes.
García DC; Miceli DC; Rizo G; García EV; Valdecantos PA; Roldán-Olarte M
Zygote; 2016 Apr; 24(2):230-5. PubMed ID: 25939353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]